We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inverness Medical to Acquire Binax

By Labmedica staff writers
Posted on 17 Feb 2005
In a move to expand the company's technology base, Inverness Medical Innovations, Inc. More...
(Waltham, MA, USA) has agreed to acquire Binax, Inc. (Portland, ME, USA).

Under the terms of the agreement, Inverness will acquire all of the stock of Binax in exchange for 1.4 million shares of its common stock and additional consideration of U.S.$8.6 million in cash at closing. The agreement also provides for additional consideration to Binax shareholders of up to $11 million in cash contingent upon Binax meeting certain new-product development objectives over five years.

Inverness is a leading global supplier of advanced diagnostic devices and is exploring new opportunities for its proprietary electrochemical and other technologies in a variety of applications, including immuno-diagnostics with a focus on women's health, cardiology, and infectious disease. "We expect to benefit from Binax's established reputation in respiratory diagnostics, and we are excited about the potential new-product development opportunities,” said Ron Zwanziger, CEO of Inverness Medical.

Binax is developing rapid diagnostic kits for the identification of pathogens causing infectious diseases. "By leveraging our combined resources and expertise, we expect to be able to improve our ability to deliver significant and innovative new products to point-of-care diagnostic markets,” remarked Roger Piasio, CEO of Binax.





Related Links:
Inverness
Binax

New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hematology Consumables
Bioblood Devices
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.